Taiwan · Delayed Price · Currency is TWD SCI Pharmtech Statistics
Total Valuation
SCI Pharmtech has a market cap or net worth of TWD 6.17 billion. The enterprise value is 7.08 billion.
| Market Cap | 6.17B |
| Enterprise Value | 7.08B |
Important Dates
The next estimated earnings date is Friday, May 8, 2026.
| Earnings Date | May 8, 2026 |
| Ex-Dividend Date | Jul 1, 2025 |
Share Statistics
SCI Pharmtech has 119.51 million shares outstanding. The number of shares has decreased by -0.13% in one year.
| Current Share Class | 119.51M |
| Shares Outstanding | 119.51M |
| Shares Change (YoY) | -0.13% |
| Shares Change (QoQ) | +0.35% |
| Owned by Insiders (%) | 5.40% |
| Owned by Institutions (%) | 0.63% |
| Float | 69.80M |
Valuation Ratios
The trailing PE ratio is 57.43.
| PE Ratio | 57.43 |
| Forward PE | n/a |
| PS Ratio | 4.59 |
| PB Ratio | 1.14 |
| P/TBV Ratio | 1.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 27.99 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.58, with an EV/FCF ratio of -18.17.
| EV / Earnings | 65.93 |
| EV / Sales | 5.27 |
| EV / EBITDA | 19.58 |
| EV / EBIT | 65.17 |
| EV / FCF | -18.17 |
Financial Position
The company has a current ratio of 1.05, with a Debt / Equity ratio of 0.18.
| Current Ratio | 1.05 |
| Quick Ratio | 0.31 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | 2.42 |
| Debt / FCF | -2.53 |
| Interest Coverage | 31.45 |
Financial Efficiency
Return on equity (ROE) is 1.98% and return on invested capital (ROIC) is 2.47%.
| Return on Equity (ROE) | 1.98% |
| Return on Assets (ROA) | 1.38% |
| Return on Invested Capital (ROIC) | 2.47% |
| Return on Capital Employed (ROCE) | 2.65% |
| Weighted Average Cost of Capital (WACC) | 4.36% |
| Revenue Per Employee | 5.62M |
| Profits Per Employee | 449,264 |
| Employee Count | 239 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 1.47 |
Taxes
| Income Tax | -5.18M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.85% in the last 52 weeks. The beta is 0.13, so SCI Pharmtech's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | -33.85% |
| 50-Day Moving Average | 52.70 |
| 200-Day Moving Average | 56.13 |
| Relative Strength Index (RSI) | 45.49 |
| Average Volume (20 Days) | 167,997 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SCI Pharmtech had revenue of TWD 1.34 billion and earned 107.37 million in profits. Earnings per share was 0.90.
| Revenue | 1.34B |
| Gross Profit | 351.03M |
| Operating Income | 155.25M |
| Pretax Income | 102.19M |
| Net Income | 107.37M |
| EBITDA | 402.45M |
| EBIT | 155.25M |
| Earnings Per Share (EPS) | 0.90 |
Balance Sheet
The company has 74.80 million in cash and 987.18 million in debt, with a net cash position of -912.39 million or -7.63 per share.
| Cash & Cash Equivalents | 74.80M |
| Total Debt | 987.18M |
| Net Cash | -912.39M |
| Net Cash Per Share | -7.63 |
| Equity (Book Value) | 5.39B |
| Book Value Per Share | 45.14 |
| Working Capital | 54.05M |
Cash Flow
In the last 12 months, operating cash flow was 220.32 million and capital expenditures -610.00 million, giving a free cash flow of -389.68 million.
| Operating Cash Flow | 220.32M |
| Capital Expenditures | -610.00M |
| Depreciation & Amortization | 247.20M |
| Net Borrowing | -49.90M |
| Free Cash Flow | -389.68M |
| FCF Per Share | -3.26 |
Margins
Gross margin is 26.12%, with operating and profit margins of 11.55% and 7.99%.
| Gross Margin | 26.12% |
| Operating Margin | 11.55% |
| Pretax Margin | 7.61% |
| Profit Margin | 7.99% |
| EBITDA Margin | 29.95% |
| EBIT Margin | 11.55% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.75, which amounts to a dividend yield of 1.45%.
| Dividend Per Share | 0.75 |
| Dividend Yield | 1.45% |
| Dividend Growth (YoY) | 20.00% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 166.95% |
| Buyback Yield | 0.13% |
| Shareholder Yield | 1.58% |
| Earnings Yield | 1.74% |
| FCF Yield | -6.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 27, 2023. It was a forward split with a ratio of 1.125.
| Last Split Date | Jul 27, 2023 |
| Split Type | Forward |
| Split Ratio | 1.125 |
Scores
SCI Pharmtech has an Altman Z-Score of 3.86 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.86 |
| Piotroski F-Score | 5 |